Aprise is a non-invasive, continuous blood glucose monitoring device.

Boulder, CO, June 12, 2006 --- Glucon Inc., developer of innovative continual blood glucose monitoring devices, announced the complete results of its recent clinical study of Aprise at the American Diabetes Association’s 66th Scientific Sessions, in Washington, D.C., June 9-13, 06 The data are also published in the Scientific Sessions Abstract Book, the June supplement to the journal Diabetes.

Dr. Ram Weiss presented Glucon’s poster, titled Non Invasive Continuous Glucose Monitoring - Results from the First 62 Subjects. The presentation is part of the Clinical Therapeutics/New Technology Glucose Monitoring and Sensing category, number 408-P in the Poster Session in the Exhibit Hall. Dr. Weiss is a senior pediatric endocrinologist at Hadassah - Hebrew University School of Medicine in Jerusalem.

“Of the personal, non-invasive, continual blood glucose technologies currently in development, Glucon’s Aprise is the most advanced in the clinical investigation process,” noted Glucon’s CEO Dan Goldberger.

The analysis of the data generated by the 62 subjects included 979 pairs of reference values and prospective, sensor derived glucose determinations. The mean absolute relative difference (RAD) of the sample was 19.9% with a median RAD of 13.2%. The mean and median differences were both around -5 -6 mg/dl indicating a slight over estimation of the sensor. When all of the results were plotted using the Clarke error grid (figure 1), 66.5%, 28.1%, 1%,4.4% and 0% were within the A, B, C, D and E ranges respectively.

“When the three study protocols were analyzed separately, the mean RAD for the oral glucose tolerance tests and the meal tolerance tests was superior to the mean RAD of the glucose infusion studies (17% vs. 19% vs. 22% respectively). Similarly, the prevalence of range D errors in the Clark error grid was smaller in OGTTs vs. meal tolerance tests and glucose infusion studies (2.1% vs. 5% vs. 8.6% respectively),” said Dr. Weiss.

Aprise™ is intended for self monitoring diabetic patients. It is the only device able to read blood glucose levels directly from a blood vessel, without puncturing the skin, through the use of a novel Photoacoustic (optical and sound-based) technology, proven to be superior to optics alone. The reading can be updated every five minutes or faster, allowing patients to respond to real time information. Aprise also signals when glucose levels rise or fall beyond acceptable levels.

“The study data further supports earlier findings that Aprise performs favorably in comparison to conventional finger stick glucose monitoring devices. We are currently developing the next generation of Aprise, which will be even smaller, lighter weight and comfortable to wear,” said Glucon President Ron Nagar.

About Glucon
Glucon (www.glucon.com) is developing a pipeline of automated, continual, blood glucose (sugar) monitoring devices for home and clinical use. Glucon was founded in 2000 by Israeli scientists including Company President Ron Nagar. The company’s flagship product, Aprise, is currently undergoing extensive clinical trials. Seed financing was provided by InnoMed Ventures. Additional investors include Giza Venture Capital, Infinity Venture Capital Fund, Ascend Technology Ventures, and several others.

Press Contact: Marjie Hadad, Media Liaison, Glucon, marjie@glucon.com or +972-54-536-5220.

Glucon Company Profile
May 2006

Glucon has developed two new products which will change the way blood glucose levels are measured both at home and in the hospital: Aprise™ and OPTImus™.

Glucon’s well known consumer product in development, Aprise, is a non-invasive, continual and real-time blood glucose monitoring device. Aprise employs a novel Photoacoustic (optical and sound-based) technology protected by several granted and pending patents. Aprise products will be small, light-weight and conveniently wearable personal devices. Glucon has shown that Photoacoustics, a unique combinatorial technology, is superior to optics alone. It provides improved specificity (identification) and sensitivity (detection of level changes) of the glucose measurement, by obtaining blood glucose measurements directly from inside a peripheral blood vessel. The Company's desktop prototype device is currently undergoing extensive clinical trials. Results to date show accuracy levels that compare favorably to conventional invasive blood glucose tests.

Glucon’s OPTImus is an automated, programmable, continual blood glucose monitoring system for hospitalized patients. OPTImus will provide safer, more efficient and cost effective blood glucose testing to support Tight Glycemic Control (TGC) initiatives. Numerous clinical publications have shown that TGC can significantly reduce mortality and morbidity amongst critical care patients. The Society of Critical Care Medicine (SCCM) estimates that 28% of U.S. hospitals have adopted TGC protocols and another 17% are in the process of doing so.

OPTImus works with an existing vascular access point and automatically performs a conventional blood glucose measurement. Hospital patients no longer need to endure finger sticks and care givers no longer need to risk contact with blood contaminated material. OPTImus can be programmed to deliver data at regular intervals and without error. OPTImus is now being evaluated in an advanced, international, multi-center clinical study.



Glucon was founded by Israeli scientists, led by Ron Nagar, MsC, and was incorporated in Delaware in June 2000. The Company established a wholly owned research and development subsidiary, Glucon Medical Ltd. in Israel in July 2000. Company headquarters are in Boulder, CO USA.



About Diabetes

Nearly 21 million Americans and 200 million people worldwide have diabetes. One in three people are unaware of their condition. It has also been reported that diabetes is the only major disease with a death rate that is still rising, up 22 percent since 1990. Diabetes has additionally emerged as the leading cause of kidney failure, blindness and non-traumatic amputation. It is also well documented that many hospitalized patients (diabetic and non-diabetic) suffer from stress-induced hyperglycemia. Uncontrolled high blood sugar in the hospital can lead to an increased risk of infection, complications, length of hospital stay, health care costs and mortality.

At present, hospitalized patients and diabetics at home utilize the conventional finger stick blood glucose tests, which are painful, messy, and inconvenient. Hospitalized patients treated with TGC should be tested hourly; diabetics at home should be testing five times per day or more.